# Special Issue

# Animal and Cellular Models of Alzheimer's Disease

## Message from the Guest Editors

Alzheimer's disease (AD) is a neurodegenerative condition with no cure. In the last three decades, important efforts have been made in the development and characterization of animal models of the disease, with the aim to translate the discoveries made toward the clinical setting. This Special Issue is focused on manuscripts describing and/or characterizing new animal and cellular models for AD. Special attention will be given to those works employing humanized animal models as well as studies based on human pluripotent stem cell technologies, strategies that should govern AD research in the coming years. This Special Issue is open to basic and clinical research or multidisciplinary approaches and will also cover original articles and reviews on the following topics: Characterization of new models relevant for AD;
Studies performed employing new cellular and animal models focused on AD;
Studies employing human pluripotent stem-cell-derived neuronal and glial cells for AD or other neurodegenerative conditions;
Evaluation of candidate therapies;
Modeling of Alzheimer's disease or other neurodegenerative conditions.

## Guest Editors

Dr. Juan A. García León

Dr. Kristine Freude

Dr. David Baglietto-Vargas

## Deadline for manuscript submissions

closed (31 August 2023)

# Biomedicines

mdpi.com/journal/
biomedicines

# About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

### Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

### Author Benefits

**High Visibility:**
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:**
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

**Rapid Publication:**
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).